Literature DB >> 26914337

Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.

Ahmad Rayes1, Richard L McMasters2, Maureen M O'Brien1.   

Abstract

Rearrangements of the mixed lineage leukemia (MLL) gene occur frequently in infants with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Conversions of leukemia cell lineage are rare, but occur most commonly in the setting of MLL-rearrangement. Blinatumomab is a bidirectional antibody targeting CD19 with significant activity in relapsed B-precursor ALL. We report an infant with ALL with t(4;11)(q21;q23) refractory to cytotoxic chemotherapy who was treated with blinatumomab. Following rapid initial clearance of peripheral lymphoblasts, bone marrow evaluation demonstrated a leukemic lineage switch to CD19-negative monoblastic AML. Complete remission was achieved with myeloid-directed chemotherapy.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  CD19; MLL; blinatumomab; infant; leukemia; lineage

Mesh：

Substances：

Year:  2016        PMID： 26914337     DOI： 10.1002/pbc.25953

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  53 in total

1.  The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.

Authors:  Shan Lin; Roger T Luo; Mahesh Shrestha; Michael J Thirman; James C Mulloy
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

Review 2.  Antibody-based therapies in patients with acute lymphoblastic leukemia.

Authors:  Shira Dinner; Michaela Liedtke
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.

Authors:  Sisi Zheng; Mukta Asnani; Andrei Thomas-Tikhonenko
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

4.  Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL.

Authors:  Matthias Wölfl; Mareike Rasche; Matthias Eyrich; Renate Schmid; Dirk Reinhardt; Paul G Schlegel
Journal:  Blood Adv       Date:  2018-06-26

5.  Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy.

Authors:  Fabiana Perna; Michel Sadelain
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

6.  Immunotherapy for acute lymphoblastic leukemia: from famine to feast.

Authors:  Kara L Davis; Crystal L Mackall
Journal:  Blood Adv       Date:  2016-12-27

7.  5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.

Authors:  Fabian Müller; Tyler Cunningham; Stephanie Stookey; Chin-Hsien Tai; Sandra Burkett; Parthav Jailwala; Maryalice Stetler Stevenson; Margaret C Cam; Alan S Wayne; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-05       Impact factor: 11.205

Review 8.  Mechanisms of and approaches to overcoming resistance to immunotherapy.

Authors:  Liora Schultz; Rebecca Gardner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

9.  Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.

Authors:  Maulik Vyas; Ann-Charlott Schneider; Olga Shatnyeva; Katrin S Reiners; Samir Tawadros; Stephan Kloess; Ulrike Köhl; Michael Hallek; Hinrich P Hansen; Elke Pogge von Strandmann
Journal:  Oncoimmunology       Date:  2016-07-15       Impact factor: 8.110

Review 10.  Clonal evolution in leukemia.

Authors:  Adolfo A Ferrando; Carlos López-Otín
Journal:  Nat Med       Date:  2017-10-06       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.